Abstract
Background
The potential risk and association of bovine leukemia virus (BLV) with human remains controversial as it has been reported to be both positive and negative in human breast cancer and blood samples. Therefore, establishing the presence of BLV in comprehensive human clinical samples in different geographical locations is essential.
Result
In this study, we examined the presence of BLV proviral DNA in human blood and breast cancer tissue specimens from Japan. PCR analysis of BLV provirus in 97 Japanese human blood samples and 23 breast cancer tissues showed negative result for all samples tested using long-fragment PCR and highly-sensitive short-fragment PCR amplification. No IgG and IgM antibodies were detected in any of the 97 human serum samples using BLV gp51 and p24 indirect ELISA test. Western blot analysis also showed negative result for IgG and IgM antibodies in all tested human serum samples.
Conclusion
Our results indicate that Japanese human specimens including 97 human blood, 23 breast cancer tissues, and 97 serum samples were negative for BLV.
Similar content being viewed by others
Background
Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leucosis (EBL), a form of B cell lymphoma in cattle, which is closely related to human T-cell leukemia viruses (HTLVs) [1]. BLV has spread worldwide and causes serious problems in the cattle industry [2]. Transmission of BLV within a herd can occur primarily through contact with bodily fluids containing infected lymphocytes via blood-sucking insects or through iatrogenic procedures, including repeated use of individual needles, syringes, rectal palpation gloves, and dehorners [3]. Initially, BLV infects various cell populations, but only BLV-infected B cells can induce the mono- or oligo-clonal expansion of origin of B-cells after a long latency period [1]. Eventually, BLV-induced B-cell lymphoma can occur in different organs and tissues, leading to a series of defects that cause mortality in the animal [3]. The majority of BLV-infected cattle are asymptomatic carriers of the virus, but less than 5% of infected cattle develop lymphoma [1]. This means that most infected cattle remain healthy, produce optimal amounts of milk, and are therefore, not culled from the herd. Therefore, BLV-infected B cells circulate through the blood of infected cattle and are present in beef [4], and infectious BLV-infected cell are also present in the milk of infected dairy cows [5,6,7]. This can be a means of transmission from cows to human. However, whether BLV is transmissible in humans remains unclear.
BLV naturally infects cattle, water buffalo, yaks [8] and alpaca [9,10,11], but can experimentally infect various other species, including sheep [12,13,14,15], rats [16], rabbits [16,17,18], pigs [19], chickens [19, 20] and goats [21] as well as several cell lines including human cells such as Hela cells and kidney 293T cells [22, 23]. Human cells of neural origin are also highly susceptible to BLV infection [16].
A few studies on the development of new and more sensitive methods have revealed re-emerging concern regarding the possible connection of BLV and human disease. An initial study by Buehring et al. reported the detection of antibodies against BLV p24 protein in 74% of the tested human sera [24]. A decade later, the same group also detected the BLV proviral gene tax in 44% (97/219) of human breast cancer tissue samples using in situ polymerase chain reaction (PCR), and 6% (12/215) of these samples showed the presence of viral p24 protein by immunohistochemistry [25]. Since then, either the BLV provirus (gag, env, tax, long terminal repeat (LTR)) and/or antibodies reacting to BLV antigens (p24 and gp51) have been detected in a wide range of geographical regions such as the United States [26,27,28,29], Australia [30, 31], Columbia [32], Brazil [29, 33] and Iran [34], in human breast tissue (healthy, benign, pre-malignant, or malignant), as well as in human blood and serum samples. These results indicate a high odds ratio of association between the presence of BLV DNA and breast cancer through screening the presence of BLV in the breast tissue of women with cancer and that of women without cancer using in situ PCR [26, 27, 29, 32]. BLV proviral DNA has also been detected in human squamous cell lung carcinoma [BLV proviral detection by PCR amplification with short proviral region All samples were tested for presence of the BLV proviral genome using high-sensitive PCR method described previously [47], using the TaqMan Gene Expression Master Mix (Applied biosystems, Tokyo, Japan) with moderate modifications. Six proviral gene fragments, named LTR, gag, pol, env, tax, and tax-3`LTR were amplified using primers listed in Additional file 1: Table S1. The reaction mixture (20 μL/sample) contained 500 ng of sample DNA (The amount of FLK-BLV template DNA depend on the BLV copy numbers), 0.2 mM each primer and 1X TaqMan Gene Expression Master Mix. The PCR conditions were as follows: 95 °C for 5 min, followed by 60 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 15 s, and extension at 72 °C for 30 s (extension at 72 °C for 50 s for tax-3′LTR), followed by post-extension (1 cycle of 72 °C for 4 min) and a final hold at 4 °C. PCR reaction of each sample was performed in triplicate. After amplification, the PCR products were separated by electrophoresis on a 3.0% agarose gel based on size differences. Samples were considered positive for the BLV proviral genome region only if PCR results were obtained at least twice from three different reactions for each target gene. Throughout the laboratory work with initial samples and DNA, special precautions were taken to prevent cross-contamination among test samples and positive control. DNA was extracted in a clean area, DNA-free room, using a special hood with UV light, along with nucleic acid decontamination solutions for preparing the PCR mixture as well as the addition of DNA to the reaction mix; all work with the positive control DNA, including DNA dilution based on copy number and addition of positive control into the PCR tube, was performed in another room. The indirect BLV p24 ELISA was performed based on previously described [57]. ELISA plates (Sumitomo Bakelite Co., Ltd., Tokyo, Japan) were coated with 200 ng/well recombinant BLV capsid p24 antigen diluted in 100 μL in 0.1 M NaHCO3 coating buffer (pH 9.0). After overnight incubation at 4 °C, coating buffer was removed and wells were washed for four times for 1 min per wash, with 300 μL/well/wash phosphate-buffered saline (PBS)-T buffer. Human serum specimen diluted 1:50 in sample dilution buffer (7.20 mM Na2HPO4 12H2O, 2.82 mM NaH2PO4 2H2O, 150.24 mM NaCl, 1% tween 20, and 5% skim milk) were incubated with antigens for 1 h at 37 °C, as primary antibodies. The plates were then washed and incubated at 37 °C for 30 min with HRP-conjugated goat anti-human IgG (diluted as 1/1000) (Abcam PIC., Tokyo, Japan) and goat anti-human IgM (diluted as 1/10,000) (Abcam PIC.), used as secondary antibodies. Finally, 3,3′,5,5′-tetramethylbenzidine substrate (Thermo Fisher Scientific, Rockford, CA) was applied to the plates and reacted with the test sample for 10 min in dark. The reaction was stopped adding 1 N H2SO4. OD values were measured at 450 nm with the correction at 690 nm using a EnSight™ multimode plate reader (PerkinElmer Inc., Waltham, MA). The plates were blanked on wells containing only the sample dilution buffer. All samples were run in triplicate. During each assay, to check the validity of the experiment procedure, two control systems were used: (i) Samples from two BLV-infected cattle and one cattle with no BLV infection, were used as positive and negative controls, respectively, followed by incubation with HRP-conjugated rabbit anti-bovine IgG (Thermo Fisher Scientific, Waltham, MA) (diluted as 1/2000), as the second antibody. (ii) To validate whether the human secondary antibodies (HRP-conjugated goat anti-human IgG and IgM) are active, we selected HTLV I/II antibody ELISA kit (MyBioScource Inc., San Diego, CA) and performed ELISA with replacement of secondary antibody in the kit with HRP-conjugated goat anti-human IgG and IgM. Two antibody isoforms (IgG and IgM) in human serum were assessed using a commercially available BLV indirect gp51 ELISA kit (JNC, Tokyo, Japan), according to the manufacturer’s instructions. Human serum specimens, diluted in 1:50 with the sample dilution buffer in the kit, were used as primary antibodies, followed by HRP-conjugated goat anti-human IgG (diluted as 1/1000) (Abcam PIC.) or goat anti-human IgM (diluted as 1/10,000) (Abcam PIC.) the secondary antibody. All samples were run triplicate. During each assay, to check the validity of the experiment procedure, we used two controls, as indicated in ELISA for anti-BLV p24 antibody. FLK-BLV cells and BLV-free FLK cells were lysed for 30 min on ice in 20 mM Tris–HCl (pH 7.4), 300 mM NaCl, 2 mM ethylenediaminetetraacetic acid, and 2% NP40 supplemented with a protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Lysates were mixed with SDS buffer and boiled for 5 min. Protein concentrations were determined with Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific). The proteins were then diluted in PBS to a final concentration of 10 ug/mL. Equal amounts of protein were electrophoresed by 12% SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA) using a Trans-Blot Turbo apparatus (Bio-Rad, Irvine, CA). After transfer, the membranes were incubated with blocking buffer with 8% skim milk for 30 min at room temperature and then incubated with human serums were diluted 1:50 with PBS with 5% skim milk, overnight at 4 °C. After washing, the membranes were incubated with HRP-conjugated goat anti-human IgG and IgM (1:100; Abcam PIC.) for 1 h. Sera from cattle infected with EBL and from uninfected cattle were used as positive and negative control, respectively, followed by incubation with rabbit anti-bovine IgG (1:4000; Thermo Fisher Scientific). The signals were visualized using SuperSignal™ West Femto Meximum Sensitivity Substrate (Thermo Fisher Scientific). Images were acquired using Chemiluminescent Imaging system (ATTO Corporation, Tokyo, Japan). PBS was used in place of primary antibody to adjust for any non-specific binding of the secondary antibody. Each human serum samples were tested twice on different days.ELISA for anti-BLV p24 antibody
ELISA for anti-BLV gp51 antibody
Western blotting assay
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- BLV:
-
Bovine leukemia virus
- EBL:
-
Enzootic bovine leucosis
- HTLV:
-
Human T-cell leukemia virus
- LTR:
-
Long terminal repeat
- PCR:
-
Polymerase chain reaction
- HIV:
-
Human immunodeficiency virus
- ELISA:
-
Enzyme-linked immunosorbent assay
- HRP:
-
Horseradish peroxidase
- OD:
-
Optical density
- PBS:
-
Phosphate-buffered saline
References
Aida Y, Murakami H, Takahashi M, Takeshima SN. Mechanisms of pathogenesis induced by bovine leukemia virus as a model for human T-cell leukemia virus. Front Microbiol. 2013;4:328.
Polat M, Takeshima SN, Aida Y. Epidemiology and genetic diversity of bovine leukemia virus. Virol J. 2017;14:209.
Lairmore MD. Animal models of bovine leukemia virus and human T-lymphotrophic virus type-1: insights in transmission and pathogenesis. Annu Rev Anim Biosci. 2014;2:189–208.
Olaya-Galan NN, Corredor-Figueroa AP, Guzman-Garzon TC, Rios-Hernandez KS, Salas-Cardenas SP, Patarroyo MA, Gutierrez MF. Bovine leukaemia virus DNA in fresh milk and raw beef for human consumption. Epidemiol Infect. 2017;145:3125–30.
Nakatsuchi A, Watanuki S, Borjigin L, Sato H, Bai L, Matsuura R, Kuroda M, Murakami H, Sato R, Asaji S, et al. BoLA-DRB3 polymorphism controls proviral load and infectivity of bovine leukemia virus (BLV) in milk. Pathogens. 2022;11:210.
Olson C, Driscoll DM. Bovine leukosis—investigation of risk for man. J Am Vet Med Assoc. 1978;173:1470–2.
Watanuki S, Takeshima SN, Borjigin L, Sato H, Bai L, Murakami H, Sato R, Ishizaki H, Matsumoto Y, Aida Y. Visualizing bovine leukemia virus (BLV)-infected cells and measuring BLV proviral loads in the milk of BLV seropositive dams. Vet Res. 2019;50:102.
Ma JG, Zheng WB, Zhou DH, Qin SY, Yin MY, Zhu XQ, Hu GX. First report of bovine leukemia virus infection in Yaks (Bos mutus) in China. Biomed Res Int. 2016;2016:9170167.
Gillet N, Florins A, Boxus M, Burteau C, Nigro A, Vandermeers F, Balon H, Bouzar AB, Defoiche J, Burny A, et al. Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human. Retrovirology. 2007;4:18.
Meas S, Seto J, Sugimoto C, Bakhsh M, Riaz M, Sato T, Naeem K, Ohashi K, Onuma M. Infection of bovine immunodeficiency virus and bovine leukemia virus in water buffalo and cattle populations in Pakistan. J Vet Med Sci. 2000;62:329–31.
Lee LC, Scarratt WK, Buehring GC, Saunders GK. Bovine leukemia virus infection in a juvenile alpaca with multicentric lymphoma. Can Vet J. 2012;53:283–6.
Kohara J, Konnai S, Onuma M. Experimental transmission of bovine leukemia virus in cattle via rectal palpation. Jpn J Vet Res. 2006;54:25–30.
Djilali S, Parodi AL, Levy D, Cockerell GL. Development of leukemia and lymphosarcoma induced by bovine leukemia virus in sheep: a hematopathological study. Leukemia. 1987;1:777–81.
Mammerickx M, Palm R, Portetelle D, Burny A. Experimental transmission of enzootic bovine leukosis to sheep: latency period of the tumoral disease. Leukemia. 1988;2:103–7.
Aida Y, Miyasaka M, Okada K, Onuma M, Kogure S, Suzuki M, Minoprio P, Levy D, Ikawa Y. Further phenotypic characterization of target cells for bovine leukemia virus experimental infection in sheep. Am J Vet Res. 1989;50:1946–51.
Altanerova V, Portetelle D, Kettmann R, Altaner C. Infection of rats with bovine leukaemia virus: establishment of a virus-producing rat cell line. J Gen Virol. 1989;70(Pt 7):1929–32.
Onuma M, Wada M, Yasutomi Y, Yamamoto M, Okada HM, Kawakami Y. Suppression of immunological responses in rabbits experimentally infected with bovine leukemia virus. Vet Microbiol. 1990;25:131–41.
Wyatt CR, Wingett D, White JS, Buck CD, Knowles D, Reeves R, Magnuson NS. Persistent infection of rabbits with bovine leukemia virus associated with development of immune dysfunction. J Virol. 1989;63:4498–506.
Mammerickx M, Portetelle D, Burny A. Experimental cross-transmissions of bovine leukemia virus (BLV) between several animal species. Zentralbl Veterinarmed B. 1981;28:69–81.
Altanerova V, Ban J, Kettmann R, Altaner C. Induction of leukemia in chicken by bovine leukemia virus due to insertional mutagenesis. Arch Geschwulstforsch. 1990;60:89–96.
Olson C, Kettmann R, Burny A, Kaja R. Goat lymphosarcoma from bovine leukemia virus. J Natl Cancer Inst. 1981;67:671–5.
Inabe K, Ikuta K, Aida Y. Transmission and propagation in cell culture of virus produced by cells transfected with an infectious molecular clone of bovine leukemia virus. Virology. 1998;245:53–64.
Bai L, Otsuki H, Sato H, Kohara J, Isogai E, Takeshima SN, Aida Y. Identification and characterization of common B cell epitope in bovine leukemia virus via high-throughput peptide screening system in infected cattle. Retrovirology. 2015;12:106.
Buehring GC, Philpott SM, Choi KY. Humans have antibodies reactive with Bovine leukemia virus. AIDS Res Hum Retroviruses. 2003;19:1105–13.
Buehring GC, Shen HM, Jensen HM, Choi KY, Sun D, Nuovo G. Bovine leukemia virus DNA in human breast tissue. Emerg Infect Dis. 2014;20:772–82.
Buehring GC, Shen HM, Jensen HM, ** DL, Hudes M, Block G. Exposure to bovine leukemia virus is associated with breast cancer: a case-control study. PLoS ONE. 2015;10: e0134304.
Baltzell KA, Shen HM, Krishnamurthy S, Sison JD, Nuovo GJ, Buehring GC. Bovine leukemia virus linked to breast cancer but not coinfection with human papillomavirus: Case-control study of women in Texas. Cancer. 2018;124:1342–9.
Buehring GC, DeLaney A, Shen H, Chu DL, Razavian N, Schwartz DA, Demkovich ZR, Bates MN. Bovine leukemia virus discovered in human blood. BMC Infect Dis. 2019;19:297.
Delarmelina E, Buzelin MA, de Souza BS, Souto FM, Bicalho JM, Camara RJF, Resende CF, Bueno BL, Victor RM, Galinari GCF, et al. High positivity values for bovine leukemia virus in human breast cancer cases from Minas Gerais, Brazil. PLoS ONE. 2020;15:e0239745.
Buehring GC, Shen H, Schwartz DA, Lawson JS. Bovine leukemia virus linked to breast cancer in Australian women and identified before breast cancer development. PLoS ONE. 2017;12: e0179367.
Lawson JS, Glenn WK. Multiple oncogenic viruses are present in human breast tissues before development of virus associated breast cancer. Infect Agent Cancer. 2017;12:55.
Mesa G, Ulloa JC, Uribe AM, Gutierrez MF: Bovine leukemia virus gene segment detected in human breast tissue. Open J Med Microbiol; 2013.
Schwingel D, Andreolla AP, Erpen LMS, Frandoloso R, Kreutz LC. Bovine leukemia virus DNA associated with breast cancer in women from South Brazil. Sci Rep. 2019;9:2949.
Khalilian M, Hosseini SM, Madadgar O. Bovine leukemia virus detected in the breast tissue and blood of Iranian women. Microb Pathog. 2019;135: 103566.
Robinson LA, Jaing CJ, Pierce Campbell C, Magliocco A, **ong Y, Magliocco G, Thissen JB, Antonia S. Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. Br J Cancer. 2016;115:497–504.
Miller JM, Miller LD, Olson C, Gillette KG. Virus-like particles in phytohemagglutinin-stimulated lymphocyte cultures with reference to bovine lymphosarcoma. J Natl Cancer Inst. 1969;43:1297–305.
Burridge MJ. The zoonotic potential of bovine leukemia virus. Vet Res Commun. 1981;5:117–26.
Bartsch DC, Springher F, Falk H. Acute nonlymphocytic leukemia. An adult cluster. JAMA. 1975;232:1333–6.
Olson C. Bovine lymphosarcoma (leukemia)—a synopsis. J Am Vet Med Assoc. 1974;165:630–2.
Gilden RV, Long CW, Hanson M, Toni R, Charman HP, Oroszlan S, Miller JM, Van der Maaten MJ. Characteristics of the major internal protein and RNA-dependent DNA polymerase of bovine leukaemia virus. J Gen Virol. 1975;29:305–14.
Donham KJ, Vandermaaten MJ, Miller JM, Kruse BC, Rubino MJ. Seroepidemiologic studies on possible relationships of human and bovine leukemia—brief communication. J Natl Cancer Inst. 1977;59:851–3.
Ressang AA. Examination for evidence of infection of humans with bovine leukemia-virus. Tijdschr Diergeneeskd. 1977;102:333–4.
Bender AP, Robison LL, Kashmiri SV, McClain KL, Woods WG, Smithson WA, Heyn R, Finlay J, Schuman LM, Renier C, et al. No involvement of bovine leukemia virus in childhood acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. Cancer Res. 1988;48:2919–22.
Zhang R, Jiang JT, Sun WH, Zhang JL, Huang K, Gu XW, Yang Y, Xu XL, Shi YF, Wang CM. Lack of association between bovine leukemia virus and breast cancer in Chinese patients. Breast Cancer Res. 2016;18:101.
Lee J, Kim Y, Kang CS, Cho DH, Shin DH, Yum YN, Oh JH, Kim SH, Hwang MS, Lim CJ, et al. Investigation of the bovine leukemia virus proviral DNA in human leukemias and lung cancers in Korea. J Korean Med Sci. 2005;20:603–6.
Gillet NA, Willems L. Whole genome sequencing of 51 breast cancers reveals that tumors are devoid of bovine leukemia virus DNA. Retrovirology. 2016;13:75.
Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y. Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines. Arch Virol. 2020;165:207–14.
Murakami K, Kobayashi S, Konishi M, Kameyama K, Yamamoto T, Tsutsui T. The recent prevalence of bovine leukemia virus (BLV) infection among Japanese cattle. Vet Microbiol. 2011;148:84–8.
Murakami K, Kobayashi S, Konishi M, Kameyama K, Tsutsui T. Nationwide survey of bovine leukemia virus infection among dairy and beef breeding cattle in Japan from 2009–2011. J Vet Med Sci. 2013;75:1123–6.
Slavikova K, Kettmann R, Reinerova M, Zajac V, Portetelle D, Burny A. Provirus integration of bovine leukemia-virus into DNA of infected human myeloma cells. Neoplasma. 1987;34:653–7.
Zandomeni RO, Carrera-Zandomeni M, Esteban E, Ferrer JF. The trans-activating C-type retroviruses share a distinct epitope(s) that induces antibodies in certain infected hosts. J Gen Virol. 1991;72(Pt 9):2113–9.
Zhao X, Buehring GC. Natural genetic variations in bovine leukemia virus envelope gene: possible effects of selection and escape. Virology. 2007;366:150–65.
Zhao XR, Jimenez C, Sentsui H, Buehring GC. Sequence polymorphisms in the long terminal repeat of bovine leukemia virus: evidence for selection pressures in regulatory sequences. Virus Res. 2007;124:113–24.
Giovambattista G, Takeshima SN, Ripoli MV, Matsumoto Y, Franco LA, Saito H, Onuma M, Aida Y. Characterization of bovine MHC DRB3 diversity in Latin American Creole cattle breeds. Gene. 2013;519:150–8.
Canova R, Weber MN, Budaszewski RF, da Silva MS, Schwingel D, Canal CW, Kreutz LC. Bovine leukemia viral DNA found on human breast tissue is genetically related to the cattle virus. One Health. 2021;13: 100252.
Evans AS. Causation and disease: effect of technology on postulates of causation. Yale J Biol Med. 1991;64:513–28.
Bai L, Yokoyama K, Watanuki S, Ishizaki H, Takeshima SN, Aida Y. Development of a new recombinant p24 ELISA system for diagnosis of bovine leukemia virus in serum and milk. Arch Virol. 2019;164:201–11.
Ferrer JF, Piper CE. An evaluation of the role of milk in the natural transmission of BLV. Ann Rech Vet. 1978;9:803–7.
Hopkins SG, DiGiacomo RF. Natural transmission of bovine leukemia virus in dairy and beef cattle. Vet Clin North Am Food Anim Pract. 1997;13:107–28.
Lawson JS, Salmons B, Glenn WK. Oncogenic viruses and breast cancer: mouse mammary tumor virus (MMTV), bovine leukemia virus (BLV), human papilloma virus (HPV), and Epstein-Barr Virus (EBV). Front Oncol. 2018;8:1.
Johnson ES. Cancer mortality in workers employed in cattle, pigs, and sheep slaughtering and processing plants. Environ Int. 2011;37:950–9.
Johnson ES, Cardarelli K, Jadhav S, Chedjieu IP, Faramawi M, Fischbach L, Ndetan H, Wells TL, Patel KV, Katyal A. Cancer mortality in the meat and delicatessen departments of supermarkets (1950–2006). Environ Int. 2015;77:70–5.
McLean D, Pearce N. Cancer among meat industry workers. Scand J Work Environ Health. 2004;30:425–37.
Acknowledgements
We are grateful to Japanese Red Cross Society (Tokyo, Japan) for providing donated human blood samples and sera of the same blood specimens, and Nihon University, School of Medicine, Itabashi hospital (Tokyo, Japan) for providing breast tissue and diagnosis of the invasive breast cancer. The authors thank the members of the viral infectious diseases unit (RIKEN) and laboratory of Global Infectious Diseases Control Science (The university of Tokyo) for technical assistance and helpful suggestions. We are grateful to the RIKEN BSI Research Resources Center for help with sequence analysis. We would like to thank Editage (www.editage.com) for English language editing.
Funding
This work was funded by Grant-in-Aid for Scientific Research (A) from the Japan Society for the Promotion of Science (JSPS) (Grant Number 16H02590), and the JSPS Postdoctoral Fellowship (Grant Number 18F18100).
Author information
Authors and Affiliations
Contributions
Conceived and designed the experiments: YA. Performed the experiments: MPY, SS, YM and RH. Analyzed the data: MPY, SS, RM, and YA. Validation: MPY, SS, RM, KH, RAF, and YA. Contributed reagents/materials/analysis tools: YA. Writing—original draft preparation: MPY and YA. Writing—review and editing: MPY, SS, YH, RM, ST, KH, YM, RAF, MT, and YA. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The studies were carried out in accordance with the guidelines proposed in RIKEN (Approval ID: Wako3 27-21 and Wako 30-1). No information was available on sex, occupation, age, and race/ethnicity of subject. All donors provided informed consent for the use of their blood and tissue specimen for research. All protocols involving human subjects were reviewed and approved by the Nihon Red Cross review board, the Human Research Ethics Committee of Nihon University, and RIKEN institutional review board.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Additional file 1: Table S1.
Primers used to detect BLV DNA in human blood and breast cancer tissue samples.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Yamanaka, M.P., Saito, S., Hara, Y. et al. No evidence of bovine leukemia virus proviral DNA and antibodies in human specimens from Japan. Retrovirology 19, 7 (2022). https://doi.org/10.1186/s12977-022-00592-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12977-022-00592-6